A Hims & Hers Insider Disposed of Stock as the Company Pushes Into Testosterone and Peptides. Here's What to Know

Chief Medical Officer Patrick Harrison Carroll sold 10,201 shares of Hims & Hers Health (HIMS) worth $287,158 on August 14 due to routine tax withholding obligations from RSU vesting. The sale is non-discretionary and does not reflect insider sentiment. The company is expanding into new specialties like testosterone replacement therapy, which is approaching $100 million in annual run rate, though this expansion may compress gross margins.